Study of Roxadustat in the Treatment of Acute Myocardial Infarction
Status:
Recruiting
Trial end date:
2023-08-31
Target enrollment:
Participant gender:
Summary
Depite successful primary percutaneous coronary intervention (PCI) and standardized medical
treatment, prognosis of acute ST-elevation myocardial infarction patents are still a poor,
with high morality and various complications such as heart failure. Roxadustat is a new drug
targeting hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibition and has shown
promising effect in reducing infarct size in pre-clinical studies.
This study aims to evaluate the efficacy and safety of early and short-term administration of
roxadustat in the treatment of acute ST-elevation myocardial infarction.